Stimuvax Clinical Program Temporarily Suspended
- Details
- Category: Merck Group
Merck KGaA has temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR).
Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World's Poorest Countries
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company's 13-valent pneumococcal conjugate vaccine, for infants and young children in the world's poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease.
Saudi Food and Drug Authority Suspends The Authorisation of Rosiglitazone (Avandia®)
- Details
- Category: Product
The Saudi food and Drug Authority has reviewed the safety of Rosiglitazone (Avandia®) which used in treatment of type 2 diabetes mellitus and marketed in Saudi Arabia as Avandia®.
Abbott Completes Acquisition of STARLIMS Technologies
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed its $123 million acquisition of STARLIMS Technologies Ltd., a leader in laboratory information management systems. The acquisition provides Abbott with leading products and expertise to build its position in laboratory informatics, an emerging and rapidly growing field focused on helping to manage the increasing amount of data generated in laboratories.
Jury Rules In Favour of AstraZeneca in First US Seroquel Product Liability Trial
- Details
- Category: AstraZeneca
AstraZeneca announced that a jury in a New Jersey state court in the US ruled in favour of AstraZeneca by rejecting a Louisiana plaintiff's claims that SEROQUEL caused his alleged injuries.
Roche uniquely positioned to deliver long-term growth
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system.
New PLATO Sub-Analysis of CABG Patients Presented at ACC
- Details
- Category: AstraZeneca
AstraZeneca announced results of a new analysis of the PLATO study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet BRILINTA (ticagrelor) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.
More Pharma News ...
- Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology
- Pfizer Discontinues A Phase 3 Study Of Figitumumab
- Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc.
- Roche and Biogen Idec decide to suspend Ocrelizumab treatment
- Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
- Novel Drug for Chronic Management of Hyperuricemia in Gout Patients
- Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus